Stitch Fix Inc (SFIX) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth
Revenue: $312.1 million, down 5.5% year over year and 2% quarter over quarter.
Adjusted EBITDA: $15.9 million, representing a 5.1% margin, up 380 basis points year over year.
Contribution Margin: 33%, marking the fourth consecutive quarter above 30%.
Gross Margin: 44.5%, up 110 basis points year over year.
Active Clients: 2.4 million, down 16% year over year and 2.6% quarter over quarter.
Revenue per Active Client (RPAC): $537, up 4% year over year.
Advertising Expense: 7.8% of revenue, down 160 basis points quarter over quarter.
Net Inventory: $109.6 million, down 13% year over year and 8% quarter over quarter.
Free Cash Flow: Negative $19 million for Q2.
Cash and Investments: $230 million with no debt.
Annual Revenue Guidance: Between $1.225 billion and $1.240 billion.
Annual Adjusted EBITDA Guidance: Between $40 million and $47 million.
Q3 Revenue Guidance: Between $311 million and $316 million.
Q3 Adjusted EBITDA Guidance: Between $7 million and $10 million.
Full Year Gross Margin Guidance: Approximately 44% to 45%.
Warning! GuruFocus has detected 3 Warning Sign with SFIX.
Release Date: March 11, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Stitch Fix Inc (NASDAQ:SFIX) exceeded expectations in Q2 with revenue of $312.1 million and adjusted EBITDA of $15.9 million.
The company achieved a 710 basis point sequential improvement in year-over-year revenue comps and a contribution margin of 33%, marking the fourth consecutive quarter above 30%.
Both the Men's business and Freestyle channel returned to year-over-year revenue growth, indicating positive momentum.
Investments in improving the quality of the assortment and inventory management have led to a 9% year-over-year increase in Average Order Value (AOV).
The company raised its annual guidance for fiscal 2025, reflecting confidence in continued performance improvements and strategic investments.
Net revenue for Q2 was down 5.5% year over year and 2% quarter over quarter, indicating ongoing challenges in achieving consistent revenue growth.
Active clients ended the quarter at 2.4 million, down 16% year over year and 2.6% quarter over quarter, highlighting difficulties in client retention and acquisition.
Free cash flow was negative $19 million in Q2, attributed to timing of working capital requirements related to inventory purchases.
The company anticipates continued active client declines into FY26, which could impact future revenue growth.
Despite improvements, the company faces potential challenges from tariffs and macroeconomic uncertainties, which could affect future performance.
Q: Can you provide insights into your customer demographics and how they relate to current consumer sentiment? Additionally, do you need Freestyle to expand your total addressable market (TAM)? A: Our clients span various household income levels, seeking convenience and style advice. The Stitch Fix value proposition resonates broadly, addressing shopping stress and dissatisfaction. Freestyle complements our Fix model, enhancing client engagement and wallet share, thus expanding our TAM.
Q: How are tariffs impacting your pricing strategy, and what categories are performing well? A: We have a tariff mitigation strategy to protect profitability, leveraging our diverse brand portfolio. Our private brands and national brands are strategically managed to mitigate tariff impacts. Categories like sneakers and accessories are performing well, and we're expanding non-apparel offerings.
Q: What drove the gross margin expansion in Q2, and what are your expectations for Q3? A: Q2 gross margin expansion was due to typical seasonality and strong AOV performance. We expect Q3 gross margins to remain within the 44% to 45% range, consistent with our full-year guidance.
Q: Can you provide more color on quarter-to-date trends for February and March? A: We're encouraged by the momentum, with strong performance in February and March. Our reimagined client experience and strategic initiatives have exceeded expectations, driving growth in Men's and Freestyle channels and improving trends in Women's and Fix channels.
Q: How does AOV growth impact future revenue growth, and what is your strategy for sustainable growth? A: AOV has been strong, but comping against it presents challenges. We aim for growth through both existing client engagement and active client growth. Sustainable long-term growth will come from balancing these areas.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Top Stock Movers Now: Warner Bros. Discovery, Boeing, Sunnova, and more
U.S. equities were mixed and little changed at midday as the market focused on new trade talks between the U.S. and China. Warner Bros. Discovery will split its TV properties from its streaming and movie studio businesses. Rooftop solar power provider Sunnova Energy International filed for bankruptcy as demand for solar panels in homes tumbles.U.S. equities were mixed and little changed at midday as the markets awaited any news from the trade talks between the U.S. and China that began today. The S&P 500 and Nasdaq rose, but the Dow Jones Industrial Average fell. Warner Bros. Discovery (WBD) was the best-performing stock in the S&P 500 after the media giant announced it was splitting itself into two publicly traded companies, dividing its television properties from its streaming and studio businesses. Shares of Boeing (BA) gained when the aircraft maker landed its first plane in China after the easing of trade tensions with the U.S. led Beijing to allow deliveries of its jets again. Qualcomm (QCOM) shares rose when the chipmaker purchased British-based wired connectivity firm Alphawave for $2.4 billion, boosting its expansion into artificial intelligence (AI) data centers. Intuitive Surgical (ISRG) shares slumped as Deutsche Bank downgraded the stock and lowered the price target, pointing to increased competition for the maker of the da Vinci surgical robot. Shares of The Children's Place (PLCE) sank when the children's products retailer's loss soared and sales fell short of estimates, which it blamed on consumer concerns about the economy and tariffs. Trading in Sunnova Energy International (NOVA) was halted after shares plunged 30% in the premarket when the rooftop solar provider filed for bankruptcy as demand for residential solar panels sinks. Oil and gold futures advanced. The yield on the 10-year Treasury note declined. The U.S. dollar lost ground to the euro, pound, and yen. Prices for most major cryptocurrencies were higher. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
